Abstract
Neurological diseases, especially degenerative diseases, have been mainly treated symptomatically with small molecule drugs. In recent years, however, the development of antibody therapeutics, nucleic acid therapeutics, and gene therapies that selectively act on specific proteins, RNA, and DNA has been underway to identify disease-modifying drugs that improve disease outcomes by acting on the underlying pathogenic mechanisms of diseases. It is expected to enable disease-modifying therapy not only for neuroimmunological and functional diseases, but also for neurodegenerative diseases caused by loss of protein function and accumulation of abnormal proteins.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
